BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11430206)

  • 1. Neoadjuvant strategies for pancreatic cancer.
    Evans DB; Wolff RA; Crane CH
    Oncology (Williston Park); 2001 Jun; 15(6):727-37; discussion 741-4, 747. PubMed ID: 11430206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
    Shah AP; Strauss JB; Leslie WT; Shah A; Mahon B; Abrams RA
    Oncology (Williston Park); 2008 Nov; 22(13):1524-9. PubMed ID: 19133606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
    [No Abstract]   [Full Text] [Related]  

  • 4. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
    J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
    Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB
    J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
    Pisters PW; Hudec WA; Lee JE; Raijman I; Lahoti S; Janjan NA; Rich TA; Crane CH; Lenzi R; Wolff RA; Abbruzzese JL; Evans DB
    J Clin Oncol; 2000 Feb; 18(4):860-7. PubMed ID: 10673529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
    Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodality management of localized pancreatic cancer.
    Wayne JD; Wolff RA; Pisters PW; Evans DB
    Cancer J; 2001; 7 Suppl 1():S35-46. PubMed ID: 11504284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
    Sohal DPS
    Chin Clin Oncol; 2017 Jun; 6(3):26. PubMed ID: 28705003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
    Hong TS; Ryan DP; Borger DR; Blaszkowsky LS; Yeap BY; Ancukiewicz M; Deshpande V; Shinagare S; Wo JY; Boucher Y; Wadlow RC; Kwak EL; Allen JN; Clark JW; Zhu AX; Ferrone CR; Mamon HJ; Adams J; Winrich B; Grillo T; Jain RK; DeLaney TF; Fernandez-del Castillo C; Duda DG
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):830-8. PubMed ID: 24867540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
    Pisters PW; Abbruzzese JL; Janjan NA; Cleary KR; Charnsangavej C; Goswitz MS; Rich TA; Raijman I; Wolff RA; Lenzi R; Lee JE; Evans DB
    J Clin Oncol; 1998 Dec; 16(12):3843-50. PubMed ID: 9850029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.
    Breslin TM; Janjan NA; Lee JE; Pisters PW; Wolff RA; Abbruzzese JL; Evans DB
    Front Biosci; 1998 Nov; 3():E193-203. PubMed ID: 9792895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.